| CAS NO: | 2070015-26-6 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| Molecular Weight (MW) | 606.2 |
|---|---|
| Formula | C31H31N5O2S2.HCl |
| CAS No. | 2070015-26-6 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 100 mg/mL (165 mM) |
| Water: <1 mg/mL | |
| Ethanol: 5 mg/mL (8.2 mM) | |
| Solubility (In vivo) | N/A |
| Synonyms | SRT3025; SRT-3025; SRT 3025; SRT3025 HCl |
| In Vitro | In vitro activity: SRT3025 inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. SRT3025 inhibits RANKL-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs) by activating AMPK and deacetylating RelA/p65 lysine 310, critical for activation of the NF-κB signaling pathway. SRT3025 acts faster than oxymetholone to improve hematopoiesis. It does not work by direct activation of Sirt1 in hematopoietic cells. SRT3025 might suppress p21 transcription through the down-regulation of Egr1. SRT3025 is found to activate wild-type Sirt1 protein but failed to activate the E230K mutant, an activation-resistant Sirt1 protein (due to a mutation at position 230). Kinase Assay: Cell Assay: Cells (HPDE, Panc-1, SU86.86, Patu8988t cells) are treated with vehicle or different concentrations of SRT3025 for 72 hours and submitted to MTT analysis. |
|---|---|
| In Vivo | SRT3025 treatment also inhibits tumor growth in Panc-1 xenografts, even though it is not as effective in inhibiting the viability of Panc-1 cells in culture. SRT3025 is well tolerated in mice and has the potential to be used in several diseases. SRT3025 administration expands HSPCs and boosts blood counts while long term SRT3025 administration does not permanently increase or decrease HSC repopulating potential. SRT3025 reduces plasma cholesterol, inflammation, and atherosclerosis in Apoe–/– mice, and it increases hepatic Ldlr expression and Pcsk9 accumulation. |
| Animal model | Female athymic nu/nu mice |
| Formulation & Dosage | Dissolved in PBS containing 1% Hydroxypropyl)-β-cyclodextrine and 12% propylene glycol; 50-200 mg/kg; p.o. administration. |
| References | Clin Cancer Res. 2016 May 15;22(10):2496-507; PLoS One. 2015 Jul 30;10(7):e0134391; Stem Cell Res. 2015 Jul;15(1):130-40. |
m.cnreagent.com